LAG3 Protein (AA 18-449) (Fc Tag)
Quick Overview for LAG3 Protein (AA 18-449) (Fc Tag) (ABIN5674617)
Target
See all LAG3 ProteinsProtein Type
Biological Activity
Origin
Source
Purity
-
-
Protein Characteristics
- AA 18-449
-
Purification tag / Conjugate
- This LAG3 protein is labelled with Fc Tag.
-
Sequence
- AA 18-449
-
Characteristics
- This protein carries a mouse IgG2a Fc tag at the C-terminus. The protein has a calculated MW of 73.7 kDa. The protein migrates as 78-92 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
-
Endotoxin Level
- Less than 1.0 EU per μg by the LAL method.
-
-
Want other Options for this Protein ?
!Discover Our Predefined Custom Proteins and Custom Protein Services!Your project requires further customization? Contact us and discover our custom protein solutions
-
-
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Buffer
- Tris with Glycine, Arginine and NaCl, pH 7.5
-
Handling Advice
- Please avoid repeated freeze-thaw cycles.
-
Storage
- -20 °C
-
-
-
: "Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy." in: mAbs, Vol. 11, Issue 6, pp. 1139-1148, (2019) (PubMed).
-
: "Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy." in: mAbs, Vol. 11, Issue 6, pp. 1139-1148, (2019) (PubMed).
-
- LAG3 (Lymphocyte-Activation Gene 3 (LAG3))
-
Alternative Name
- LAG-3
-
Background
- Lymphocyte activation gene 3 protein (LAG3) is also known as CD antigen CD223 and protein FDC, which belongs to immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 /CD223 involved in lymphocyte activation. LAG3 /CD223 binds to HLA class-II antigens.
-
Molecular Weight
- 73.5 kDa
-
NCBI Accession
- XP_005570011
-
Pathways
- Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints
Target
-